Search
Sarilumab
go.drugbank.com/drugs/DB11767ApprovedInvestigationalSarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sariluma...
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersCapmatinib
go.drugbank.com/drugs/DB11791ApprovedInvestigationalCapmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesNiraparib
go.drugbank.com/drugs/DB11793ApprovedInvestigationalNiraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First appr...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 InducersBictegravir
go.drugbank.com/drugs/DB11799ApprovedInvestigationalBictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesArtefenomel
go.drugbank.com/drugs/DB11809InvestigationalArtefenomel has been investigated for the treatment of Malaria.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsBaricitinib
go.drugbank.com/drugs/DB11817ApprovedInvestigationalBaricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthrit...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesErtugliflozin
go.drugbank.com/drugs/DB11827ApprovedInvestigationalErtugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 20...
Categories: P-glycoprotein substratesPritelivir
go.drugbank.com/drugs/DB11844InvestigationalPritelivir has been used in trials studying the prevention of HSV-2 and Genital Herpes.
Categories: P-glycoprotein substratesRevefenacin
go.drugbank.com/drugs/DB11855ApprovedInvestigationalRevefenacin is a novel biphenyl carbamate tertiary amine agent that belongs to the family of the long-acting muscarinic antagonists (LAMA). The labile primary amide in the structure produces a "soft-drug" site that allows rapid systemic ...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesRufloxacin
go.drugbank.com/drugs/DB13772InvestigationalRufloxacin is a quinolone antibiotic.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors